Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. This is why it happened. Find the latest press releases from Jaguar Health, Inc. Common Stock (JAGX) ... See All News + Insights. Nearly 8.01% of Jaguar Health, Inc.’s shares belong to company insiders and institutional investors own 6.7% of the company’s shares, according to Thomson Reuters’ data. Read more. This is a stock that has made some serious moves lately. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. A high-level overview of Jaguar Health, Inc. (JAGX) stock. Options Dashboard Options Portfolios Options Screener Compare . The stock price of Jaguar Health Inc (NASDAQ: JAGX) increased over 40% shortly after the market opened this morning. Jaguar Health employs 29 workers across the globe. & Chief Accounting Officer, Chair of Scientific Advisory Board & Acting Chief Scientific Officer, Sr. Director of Investor Relations, Bus. It operates through two reportable segments, Human Health and Animal Health. Post-Market 0.02 (0.95%) Is the Parabolic Rise of JAGX Stock Too Good to Be True? Stocks Dashboard Top 5 Stocks Stock Screener Sector & Industry Options . MarketBeat just released five new trading ideas, but Jaguar Health wasn't one of them. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Jaguar Health against related stocks people have … As of February 12th, there was short interest totaling 3,490,000 shares, a drop of 41.3% from the January 28th total of 5,950,000 shares. The biotechnology company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by $0.10. Its human health product pipelines include crofelemer, which is in Phase III clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, idiopathic/functional diarrhea, and irritable bowel; and SB-300, a second-generation anti-secretory agent for various indications, including cholera. Jaguar Health continues to heat up, but JAGX stock is moving higher on a lot of hope. Jaguar Health's management team includes the following people: J.D., M.B.A., Chief of Staff, Chief Compliance Officer & Gen. Jaguar Health has received 87.59% “outperform” votes from our community.
Temple Of Edfu Location,
élection Présidentielle Côte D'ivoire 2020 Date,
Charles Njonjo Married At 52,
Morogoro Population 2019,
Unfall A81 Heute Gärtringen,
Ella Big Brother Instagram,
Red Bull Radtrikot,
Urlaub Rimini All-inclusive,